Cost-Effective Management of Malignant Potentially Fatal Asthma

$39.50 plus tax (Refund Policy)

Buy Article:

Abstract:

Asthma mortality is rising, and noncompliance may be a contributing factor to asthma deaths. We have established a comprehensive treatment program for our most severe asthmatic patients, who are also noncompliant. The objective was to evaluate the effect of a treatment protocol for patients with malignant potentially fatal asthma on both clinical outcome and inpatient costs. A retrospective chart review of eight patients diagnosed with malignant potentially fatal asthma was conducted. Patients were initially evaluated in consultation either at Northwestern Memorial Hospital or in the Allergy-Immunology Clinic at Northwestern Medical Faculty Foundation. The patients all met at least one of the criteria for potentially fatal asthma and each patient was noncompliant with medical care, as they did not follow their doctor's instructions, did not keep scheduled appointments, and/or did not take prescribed medications. A treatment program that included regularly scheduled visits with the same attending physician and physician in training, patient and family education, 24-hour telephone access, adequate doses of anti-inflammatory medication, and psychiatric referral, if indicated, was instituted. The number of admissions to the hospital, including intensive care unit admissions and emergency room visits was tabulated, as was the total cost per year per patient for hospital treatment of asthma before and after starting the treatment program. The number of hospitalizations markedly declined, with three of the eight patients requiring no further admissions to the hospital and three additional patients not requiring admission for at least 4 years. There were no fatal events and no further intensive care unit admissions. The mean cost per person per year for in-patient care before intervention was $22,999 ± $20.639, and the mean postintervention cost per patient per year was $1107 ± $1618. This was a statistically significant cost savings (P < 0.0017). We developed a comprehensive treatment program that has enabled us to successfully and cost effectively treat patients with malignant potentially fatal asthma.

Document Type: Research Article

DOI: http://dx.doi.org/10.2500/108854197778605455

Publication date: March 1, 1997

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more